Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.
Tamer I. Khayal net worth and biography

Tamer Khayal Biography and Net Worth

Insider of TransMedics Group
Dr. Tamer I. Khayal M.D. serves as Chief Commercial Officer of the Company. He served as our Chief Medical Officer and Vice President of Clinical Development from 2006 to 2017 and as our Director of Clinical Development from 2001 to 2006. Prior to joining TransMedics, Dr. Khayal served for six years as Director of Clinical Affairs for Zentiva Group, a.s., a pharmaceutical company, where he led clinical research, regulatory filings and clinical sales training for the company’s Middle East and Africa operations. Prior to his employment in the pharmaceutical industry, Dr. Khayal was a practicing physician.

What is Tamer I. Khayal's net worth?

The estimated net worth of Tamer I. Khayal is at least $54,184.00 as of August 24th, 2022. Dr. Khayal owns 1,300 shares of TransMedics Group stock worth more than $54,184 as of September 26th. This net worth approximation does not reflect any other investments that Dr. Khayal may own. Additionally, Dr. Khayal receives a salary of $551,370.00 as Insider at TransMedics Group. Learn More about Tamer I. Khayal's net worth.

How old is Tamer I. Khayal?

Dr. Khayal is currently 53 years old. There are 3 older executives and no younger executives at TransMedics Group. The oldest executive at TransMedics Group is Mr. John F. Carey, VP of Operations, who is 57 years old. Learn More on Tamer I. Khayal's age.

What is Tamer I. Khayal's salary?

As the Insider of TransMedics Group, Inc., Dr. Khayal earned a total compensation package of $1,991,552.00 in 2021. Dr. Khayal earned a salary of $386,250.00, options awards of $1,440,180.00, non-equity compensation of $165,122.00, and no other miscellaneous compensation. The highest earning executive at TransMedics Group is Dr. Waleed H. Hassanein M.D., Founder, Pres, MD, CEO & Director, who commands a salary of $992,420.00 per year. Learn More on Tamer I. Khayal's salary.

How do I contact Tamer I. Khayal?

The corporate mailing address for Dr. Khayal and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected] Learn More on Tamer I. Khayal's contact information.

Has Tamer I. Khayal been buying or selling shares of TransMedics Group?

Tamer I. Khayal has not been actively trading shares of TransMedics Group during the last quarter. Learn More on Tamer I. Khayal's trading history.

Who are TransMedics Group's active insiders?

TransMedics Group's insider roster includes John Carey (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), and Tamer Khayal (Insider). Learn More on TransMedics Group's active insiders.

Are insiders buying or selling shares of TransMedics Group?

In the last year, TransMedics Group insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $2,256,000.00. In the last year, insiders at the sold shares 22 times. They sold a total of 244,781 shares worth more than $9,028,190.48. The most recent insider tranaction occured on September, 7th when CEO Waleed H Hassanein sold 2,277 shares worth more than $125,235.00. Insiders at TransMedics Group own 8.7 % of the company. Learn More about insider trades at TransMedics Group.

Information on this page was last updated on 9/7/2022.

Tamer I. Khayal Insider Trading History at TransMedics Group

See Full Table

Tamer I. Khayal Buying and Selling Activity at TransMedics Group

This chart shows Tamer I. Khayal's buying and selling at TransMedics Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TransMedics Group Company Overview

TransMedics Group logo
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More

Today's Range

Now: $41.68
Low: $40.83
High: $42.61

50 Day Range

MA: $45.92
Low: $32.21
High: $55.75

2 Week Range

Now: $41.68
Low: $10.00
High: $56.41

Volume

459,000 shs

Average Volume

316,848 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.